PCE

Respiratory Syncytial Virus (RSV) significantly impacts adults, especially those over age 60 and those with chronic conditions.In this podcast, nurse practitioners Drs. Carrico and Stevenson discuss the underestimated burden of RSV. The podcast also explores practical strategies for increasing vaccine uptake that you can apply to your practice starting today so that you can protect your patients against RSV.Listen as they discuss:The Burden of Adult RSVRSV Vaccines for Adults: Data and RecommendationsRSV Vaccine UptakePractical Strategies to Increase RSV Vaccine UptakeFaculty:Dr. Ruth Carrico is a family nurse practitioner and senior consultant with Carrico & Ramirez, PLLC focused on infectious diseases, infection prevention and control, and vaccinology.  She is based in Louisville, Kentucky and is a Professor, adjunct faculty, with the University of Louisville School Medicine, Division of Infectious Diseases. Dr. Carrico has received training specific for healthcare epidemiology at the Centers for Disease Control and Prevention (CDC) in conjunction with the Rollins School of Public Health at Emory University in Atlanta and the Society for Healthcare Epidemiology of America (SHEA). Dr. Carrico has worked in the field of infectious diseases and infection control for more than thirty years.  Dr. Carrico also maintains a clinical practice focused on vaccines, vaccination, and immunization processes.Dr. Audrey M. Stevenson is a family nurse practitioner with over 40 years of clinical, public health, and leadership experience. Dr. Stevenson, who holds a master of public health and master of nursing degrees, received her doctorate in public health from the University of Utah. She formerly worked in public health for over 34 years and was the former Division Director of Family Health and Clinical Services of the Salt Lake County Health Department in Salt Lake City, Utah. She currently works as a consultant and teaches graduate FNP and MPH students at two universities. Dr. Stevenson is also a member of the statewide vaccine advisory board, where she collaborates on vaccine policies and recommendations for the state. Previously, Dr. Stevenson served as Vaccination Branch Director for the COVID-19 Incident Command for Salt Lake County, where she directed the vaccination strategies for 1.2 million residents of Salt Lake County. She has been a vaccine champion for over 30 years. Learn more:Download this practical infographic to help you integrate RSV vaccination into your clinical practice.https://bit.ly/43mzacqFor more information for nurses, subscribe to the PCE podcast channel on your favorite player! 

Listen in as Evette Whaley and Katie Smiley PA-C talk about innovative strategies for NPs and PAs to improve treatment for pediatric patients with atopic dermatitis. They discuss how to assess the whole patient and their family to better understand the impact of the disease on their quality of life. They also discuss newer treatments and how they can be incorporated into a comprehensive management plan for pediatric patients and their caregivers. Presenters:Evette WhaleyCaregiverBaltimore, Maryland Katie Smiley PA-CGrants & Clinical DirectorProgram Coordinator, Multidisciplinary Atopic Dermatitis ProgramAllergy & Asthma Medical GroupRady Children's HospitalSan Diego, CaliforniaLink to full program:https://bit.ly/43svVyJ

Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program: bit.ly/4gkTzSv

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, Jona Tanguay, MMSc, PA-C, AAHIVS discusses considerations to review with patients to empower them to make their own informed choices in PrEP selection, including:Leveraging PrEP options with unique dosing schedules and/or routes such as long-acting cabotegravir and on-demand 2-1-1 FTC/TDFDifferences in adverse effect profiles between 4 PrEP optionsPotential for HIV resistanceRequirements for compliance and monitoringEvidence in populations with various acquisition behaviorsDrug interaction implications Faculty: Jona Tanguay, MMSc, PA-C, AAHIVSHealth Care Provider and HIV Specialist Whitman-Walker HealthVice President for Education, GLMA: Health Professionals Advancing LGBTQ EqualityClinical Instructor, Yale University School of Nursing Washington, DC Link to full program: https://bit.ly/41WF54o

In this episode, Dr. Battista and Dr. Parsons discuss the importance of care guidelines and the multidisciplinary team in the treatment of spinal muscular atrophy (SMA). This overview will include:The role each member of the interdisciplinary team plays in the care of SMA including physical therapists, occupational therapists, and speech therapistsThe importance of continued, ongoing therapy in addition to medication therapy to provide the greatest improvement in SMA careHow to manage transitions in care, including the transition from pediatrics to adulthood and how to include the necessary support teamsThe role shared decision-making plays in the treatment of patients with SMAPresenters:Julie Parsons, MDCo-Director, Neuromuscular ClinicHaberfeld Family Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyChildren's Hospital ColoradoDenver, ColoradoVanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCNSenior Director of Nursing, Palliative CarePsychosocial Oncology and Palliative CareDana-Farber Cancer InstituteBoston, MassachusettsSupported by an educational grant from Biogen.Link to full program: https://bit.ly/43Dmo7qLink to CME: Claim credithttps://bit.ly/40gulfX 

In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes:Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplamDiscussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complicationsReview of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDAPresenters:Julie Parsons, MDCo-Director, Neuromuscular ClinicHaberfeld Family Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyChildren's Hospital ColoradoDenver, ColoradoVanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCNSenior Director of Nursing, Palliative CarePsychosocial Oncology and Palliative CareDana-Farber Cancer InstituteBoston, MassachusettsSupported by an educational grant from BiogenLink to full program:bit.ly/41kw2dKLink to CME: Claim credit -bit.ly/40fkDKD 

In this episode, Julie Parsons, MD, discusses the genetic diagnosis of spinal muscular atrophy (SMA), anticipated clinical findings, the importance of newborn screenings, and the next steps to consider after a positive diagnosis is obtained. This high-level overview includes:SMA as an autosomal recessive diseaseDifferences in spinal motor neurons (SMN) 1 and 2 at the time of diagnosis and how these drive severity of diseaseImportant clinical findings in the diagnosis of SMA, as every child may not be identified with newborn screeningThe importance of newborn screening and critical next steps and logistical considerations when receiving a positive screen in your practicePresenters:Julie Parsons, MDCo-Director, Neuromuscular ClinicHaberfeld Family Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyChildren's Hospital ColoradoDenver, ColoradoVanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCNSenior Director of Nursing, Palliative CarePsychosocial Oncology and Palliative CareDana-Farber Cancer InstituteBoston, Massachusetts Supported by an educational grant from BiogenLink to full program: bit.ly/41kw2dKLink to CME: Claim credit - bit.ly/40eyBwr 

In this episode, Vikramjit Mukherjee, MD, and Cameron Smith, MPAS, PA-C, answer audience questions on how best to care for hospitalized patients with COVID-19 from a live, virtual question and answer webinar. This episode includes expert insights on:Viral coinfections such as influenza and RSVNew data comparing baricitinib and tocilizumab for patients with severe COVID-19Management of bacterial and fungal coinfection while incorporating antimicrobial stewardshipTips for transitioning patients out of the ICU and to the medical floor or homePresenters:Vikramjit Mukherjee, MDAssistant Professor  Division of Pulmonary, Critical Care, & Sleep Medicine  New York University School of Medicine  DirectorMedical Intensive Care UnitBellevue HospitalNew YorkCameron Smith MPAS, PA-CLead Advanced Practice ProviderMedical Intensive Care UnitBellevue HospitalNew York Health and Hospitals  New YorkContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. Link to full program: bit.ly/3z52c00

In this episode, Vikramjit Mukherjee, MD, and Cameron Smith, MPAS, PA-C, answer audience questions on how best to care for hospitalized patients with COVID-19 from a live, virtual question and answer webinar. This episode includes expert insights on:Supportive care management such as oxygen support, glycemic control, and anticoagulationEscalation of therapy in patients with worsening oxygen requirementsUse of remdesivir in patients with renal dysfunctionBrief commentary on long COVIDPresenters:Vikramjit Mukherjee, MDAssistant Professor  Division of Pulmonary, Critical Care, & Sleep Medicine  New York University School of Medicine  DirectorMedical Intensive Care UnitBellevue HospitalNew YorkCameron Smith MPAS, PA-CLead Advanced Practice ProviderMedical Intensive Care UnitBellevue HospitalNew York Health and Hospitals  New York, New YorkContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc.bit.ly/3z52c00

In this podcast, Susan LeLacheur, DrPH, PA-C, AAHIVS discusses racial disparities in access to HIV prevention (PrEP) and strategies to close these gaps, including:Incorporating comprehensive sexual history into medical appointments and offering PrEP to all sexually active patientsIncrease awareness of PrEP access programs in communities of colorDiversification of the medical workforceFaculty: Susan LeLacheur, DrPH, PA-C, AAHIVSProfessorDepartment of Physician Assistant StudiesSchool of Medicine and Health SciencesThe George Washington UniversityWashington, DCLink to full program: https://practicingclinicians.com/content/hiv-prevention-resource-center

This podcast episode is part of a multimedia program reviewing the management of nontuberculous mycobacterial lung disease (NTM-LD). Tune in to hear Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC, and Anne O'Donnell, MD, highlight the diagnostic criteria and optimal treatment strategies in patients with NTM-LD. The overview will include: Recommended assessments and tests to appropriately diagnosis NTM-LD in patientsA summary of the current guidelines for the management of NTM-LD, including appropriate monitoring of medications.Guidance on how to individualize treatment plans for patients with NTM-LD based on disease and patient characteristicsPresenters: Jennifer Faber-Gerling, RN, MS, CNS, ANP-BCNurse PractitionerDivision of Mycobacterial and Respiratory InfectionsNational Jewish HealthDenver, ColoradoAnne O'Donnell, MDProfessor of MedicineDivision of Pulmonary, Critical Care, and Sleep MedicineGeorgetown University Medical CenterWashington, DCTo view other program offerings, including a CE-certified on-demand webcast, a Q&A text module, and to download slides, visitpce.is/NTM.

In this episode, Tracy Zivin-Tutela, MD, answers audience questions on how best to care for patients at high risk of complications due to influenza from a live virtual meeting series. This episode includes expert insights on:Emerging resistance patterns of currently used antiviralsGetting the flu vaccine after treatment with antiviralsUse of antivirals in patients who test positive for flu and COVID-19Techniques and over-the-counter therapies other than yearly vaccination to avoid severe complications due to the flu Avoiding dairy after receiving baloxavirInsurance coverage for antiviralsConsidering bacterial and viral coinfection in patients with lung diseaseRetreating high-risk patients with antivirals after another flu exposureCalculating flu ratesPresenter:Tracy Zivin-Tutela, MDAttending PhysicianDivision of Infectious DiseasesDepartment of MedicineLos Alamitos Medical Center, Fountain Valley Regional HospitalNew Brunswick, CaliforniaDaniel Zalinov, PA-CAtrium HealthCharlotte, North CarolinaLink to full program:https://bit.ly/3GMokRC

In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCSdiscuss timely recognition of MS, including insights into why early recognition can lead to early treatment, which can decrease the risk of disability progression and produces better outcomes. Challenges discussed include the variable clinical presentation of MS and the lack of specific tests. The experts also discuss how to avoid missed diagnosis and misdiagnosis.  Stephen Krieger, MD: consultant/advisor/speaker: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics; researcher: Biogen, Bristol-Myers Squibb, Novartis, Sanofi.Allison L. Boyd, MPAS, PA-C, MSCS: consultant/advisor/speaker: EMD Serono.  

In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCSdiscuss the expanding treatment armamentarium for MS, the complexities involved in making treatment selection, patient factors to consider when individualizing treatment, and how best to talk with patients about their options within the context of shared decision-making.Stephen Krieger, MD: consultant/advisor/speaker: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics; researcher: Biogen, Bristol-Myers Squibb, Novartis, Sanofi.Allison L. Boyd, MPAS, PA-C, MSCS: consultant/advisor/speaker: EMD Serono.

In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCS discuss the challenges of managing patients with MS over the long-term, including assessment and management of comorbidities management, differentiating relapse from pseudorelapse, telemedicine, and the important role of NPs and PAs in multidisciplinary care. 

In this podcast, Jason E. Farley, PhD, MPH, ANP-BC shares his recommendations on the best ways to implement new HIV PrEP guidelines based on his clinical experiences.

In this podcast, Latesha Elopre, MD, MSPH, discusses how the new CDC recommendations on pre-exposure prophylaxis (PrEP) education, eligibility, and monitoring affect her clinical practice.Contributors:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesUniversity of Alabama at BirminghamBirmingham, AlabamaLatesha Elopre, MD, MSPH, has no relevant financial relationships to disclose.  

In this podcast, Latesha Elopre, MD, MSPH and Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN answer pressing questions from healthcare professionals who care for patients that may be at risk for HIV infection.Presenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesUniversity of Alabama at BirminghamBirmingham, AlabamaModeratorJason Farley, PhD, MPH, ANP-BC, FAAN AACRNEndowed Professor of Nursing Leadership and InnovationJohns Hopkins University School of NursingDirector, Center for Infectious Disease and Nursing InnovationAdult Nurse Practitioner, Infectious DiseasesJohns Hopkins MedicineBaltimore, Maryland

In this podcast, Latesha Elopre, MD, MSPH discusses options for pre-exposure prophylaxis (PrEP). Listen as she explains best practices for the nonpharmacologic prevention of HIV, as well as oral and injectable pharmacologic PrEP options.Presenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesUniversity of Alabama at BirminghamBirmingham, AlabamaModeratorJason Farley, PhD, MPH, ANP-BC, FAAN, AACRNEndowed Professor of Nursing Leadership and InnovationJohns Hopkins University School of NursingDirector, Center for Infectious Disease and Nursing InnovationAdult Nurse Practitioner, Infectious DiseasesJohns Hopkins MedicineBaltimore, Maryland

In this podcast, Latesha Elopre, MD, MSPH discusses the new CDC guideline recommendations for pre-exposure prophylaxis (PrEP). Listen as she explains the updated eligibility criteria, assessing indications for PrEP, and best practices for HIV/antibody testing.Presenter:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesUniversity of Alabama at BirminghamBirmingham, AlabamaModeratorJason Farley, PhD, MPH, ANP-BC, FAAN AACRNEndowed Professor of Nursing Leadership and InnovationJohns Hopkins University School of NursingDirector, Center for Infectious Disease and Nursing InnovationAdult Nurse Practitioner, Infectious DiseasesJohns Hopkins MedicineBaltimore, Maryland

In this podcast, Latesha Elopre, MD, MSPH discusses inequities in pre-exposure prophylaxis (PrEP) uptake and the importance of sexual health screening. Additionally, Dr Elopre shares her best practices for receiving an adequate sexual health history from her patients.Presenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesUniversity of Alabama at BirminghamBirmingham, AlabamaModeratorJason Farley, PhD, MPH, ANP-BC, FAAN AACRNEndowed Professor of Nursing Leadership and InnovationJohns Hopkins University School of NursingDirector, Center for Infectious Disease and Nursing InnovationAdult Nurse Practitioner, Infectious DiseasesJohns Hopkins MedicineBaltimore, Maryland

This podcast episode is part of a multimedia program discussing the co-management of moderate to severe atopic dermatitis (AD) in the primary care and specialty settings. Tune in to hear Dr Silverberg and NP Victoria Garcia-Albea highlight newly approved agents and the recent expanded labeling of an existing AD therapy, including: Ruxolitinib, a topical JAK inhibitor for mild to moderate AD approved in 2021 Abrocitinib and upadacitinib, oral JAK inhibitors approved in early 2022 for moderate to severe ADTralokinumab, an IL-13 inhibitor available as a subcutaneous injection, which was approved in late 2021 for moderate to severe ADExpanded approval for use in patients as young as 6 months for dupilumab, a subcutaneous IL-4 receptor α inhibitorPresenters: Jonathan Silverberg, MD, PhD, MPHAssociate ProfessorDirector of Clinical ResearchDirector of Patch TestingGeorge Washington University School of Medicine and Health SciencesWashington, DCVictoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRNDirectorLahey Dermatology Nurse Practitioner Training ProgramLahey Hospital and Medical CenterBurlington, MassachusettsTo view other program offerings, including a CE-certified recorded roundtable webcast, a ClinicalThought commentary, and to download slides, visit:https://bit.ly/3PiupXZ

In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLLUpdated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLLProgression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil as first-line therapy in CLLAssessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLLPresenterJohn M. Burke, MDRocky Mountain Cancer CentersAurora, ColoradoModerator Amy Esposito, FNP-CNurse PractitionerRocky Mountain Cancer CenterAurora, Colorado

In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCLUpdated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCLResults from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLLPreliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapiesPresenters:Tycel J. Phillips, MD Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow TransplantationAssociate Professor of MedicineUniversity of Michigan Rogel Cancer Center Ann Arbor, MichiganAmy Goodrich, RN, MSN, CRNP-ACResearch Associate, Department of MedicineJohns Hopkins UniversityNurse Practitioner, Department of MedicineThe Sidney Kimmel Comprehensive Cancer CenterBaltimore, MarylandContent supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Link to full program, including a downloadable highlights slideset:https://bit.ly/3yufCU4

In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:An overview of the PROpel study of olaparib and the TRITON study of rucaparibFDA-approved indications for olaparib and rucaparibGenetic and molecular testing for BRCA1/2 and other HRR mutationsManaging adverse events associated with olaparib and rucaparibMonitoring for and managing anemiaGastrointestinal side effectsFatigueA look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibitionPresenter:Brenda Martone, MSN, ANP-BC, AOCNPNurse PractitionerDivision of Genitourinary OncologyNorthwestern MedicineChicago, IllinoisLink to full program:PCE.is/Onc22

In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.Topics include:Currently approved ICIsRole of biomarker and PD-L1 testing in advanced NSCLCStrategies to individualize ICI treatment for patients with advanced NSCLCStrategies for identifying and managing immune-related adverse events in patients treated with ICIPresenter:Sandip P. Patel, MDAssociate ProfessorDepartment of MedicineDivision of Hematology/OncologyUniversity of California – San DiegoLa Jolla, California Link to full program:https://bit.ly/39vuCHC

In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include:An overview of the monarchE study leading to FDA approval of adjuvant abemaciclibKey trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancerManaging adverse events associated with CDK4/6 inhibitorsPromoting adherence to oral therapyPresenter:Julia LaBarbera, MSN, RN, AGACNP-BCNurse PractitionerDivision of Hematology/OncologyDepartment of MedicineUniversity of California, Los AngelesSanta Monica, CaliforniaLink to full program:PCE.is/Onc22

In this episode, Beth Sandy, MSN, CRNP provides her thoughts on key data presented at the 2022 ASCO annual conference relating to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Findings covered include:Survival results after 3 years from the phase III Checkmate 9LA study of nivolumab and ipilimumab combined with 2 cycles of chemotherapy vs chemotherapy in previously untreated advanced NSCLCUpdated survival and safety results after 5 years from the phase III Checkmate 227 study of nivolumab and ipilimumab vs chemotherapy in previously untreated advanced NSCLC, including assessment of a treatment-free intervalUpdated analysis from the phase III ATEZO-BRAIN trial of atezolizumab + carboplatin and pemetrexed in patients with advanced NSCLC with untreated brain metastases Updated overall response analysis from the phase II KEYNOTE-799 study of pembrolizumab with concurrent chemoradiation in unresectable, locally advanced stage III NSCLCResults from a phase II trial evaluating nivolumab plus ipilimumab vs nivolumab monotherapy following chemoradiation in unresectable stage III NSCLCPathological complete response results from the phase II NADIM II study of nivolumab and chemotherapy vs chemotherapy in the neoadjuvant NSCLC settingPresenter:Beth Sandy, MSN, CRNPNurse PractitionerAbramson Cancer CenterUniversity of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program:https://bit.ly/39vuCHC

In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHA Professor of MedicineTulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program: https://bit.ly/3xn238i

In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHA Professor of MedicineTulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program:https://bit.ly/3xn238i

In this podcast episode, 2 migraine experts discuss clinical pearls for individualizing migraine care from diagnosis to ongoing management. They cover patient factors to consider in the differential diagnosis, when choosing an acute treatment, and in making the decision to initiate preventive treatment. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.ContributorsMaureen Moriarty, DNP, ANP-BCAssociate Professor DirectorMalek School of Nursing ProfessionsMarymount UniversityArlington, VirginiaOwnerMoriarty AssociatesWestminster, MarylandDr Moriarty:consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly;researcher: Teva.Karen A. Williams, DNP, FNP-BC, AQHPresidentKDW Health ManagementPensacola, FloridaDr Williams: consultant/advisor/speaker: Biohaven.

This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and full program at: PCE.is/NVAF.Contributors:Program DirectorKeith C. Ferdinand, MD, FACC, FAHA,has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.FacultyDavid S. Kountz, MD, has no relevant conflicts of interest to report.Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.

This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study. Review the downloadable slideset and full program at: PCE.is/NVAF.Contributors:Program DirectorKeith C. Ferdinand, MD, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.FacultyDavid S. Kountz, MD, has no relevant conflicts of interest to report.Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.

This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF. Review the downloadable slideset and full program at: PCE.is/NVAF.Contributors:Program DirectorKeith C. Ferdinand, MD, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.FacultyDavid S. Kountz, MD, has no relevant conflicts of interest to report.Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.

This podcast is the second in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. Our moderator for the series is Mr Rick Davis, PA-C. In this episode, our panel of experts review available medication options and their current place in therapy according to recent evidence and guideline recommendations.  Presenters:Anita Afzali, MD, MPH, FACG, AGAFProfessor of Clinical MedicineAbercrombie & Fitch Endowed Chair in Inflammatory Bowel DiseaseMedical Director, OSU Inflammatory Bowel Disease CenterProgram Director, Advanced Inflammatory Bowel Disease FellowshipDivision of Gastroenterology, Hepatology, and NutritionThe Ohio State University Wexner Medical CenterColumbus, OhioNana Bernasko, DNP, CRNP, WHNP-BCAssistant ProfessorDivision of Gastroenterology and Hepatology  Department of MedicinePenn State University Medical CenterHershey, PennsylvaniaRichard H. Davis, PA-CSenior Physician AssistantDivision of Gastroenterology, Hepatology, and NutritionUniversity of Florida College of MedicineGainesville, FloridaThe content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticls, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.To access the full program, go topce.is/IBD

This podcast is the third in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, our panel of experts review strategies for individualizing care, medication response challenges, the use of therapeutic drug monitoring, and treatment de-escalation strategies.  Presenters:Anita Afzali, MD, MPH, FACG, AGAFProfessor of Clinical MedicineAbercrombie & Fitch Endowed Chair in Inflammatory Bowel DiseaseMedical Director, OSU Inflammatory Bowel Disease CenterProgram Director, Advanced Inflammatory Bowel Disease FellowshipDivision of Gastroenterology, Hepatology, and NutritionThe Ohio State University Wexner Medical CenterColumbus, OhioNana Bernasko, DNP, CRNP, WHNP-BCAssistant ProfessorDivision of Gastroenterology and Hepatology  Department of MedicinePenn State University Medical CenterHershey, PennsylvaniaThe content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticals, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.To access the full program, go topce.is/IBD 

This podcast is the first in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, the experts discuss the importance early and accurate diagnosis and classification of IBD plays in choosing appropriate and individualized therapies for disease management.  Presenters:Anita Afzali, MD, MPH, FACG, AGAFProfessor of Clinical MedicineAbercrombie & Fitch Endowed Chair in Inflammatory Bowel DiseaseMedical Director, OSU Inflammatory Bowel Disease CenterProgram Director, Advanced Inflammatory Bowel Disease FellowshipDivision of Gastroenterology, Hepatology, and NutritionThe Ohio State University Wexner Medical CenterColumbus, OhioNana Bernasko, DNP, CRNP, WHNP-BCAssistant ProfessorDivision of Gastroenterology and Hepatology  Department of MedicinePenn State University Medical CenterHershey, PennsylvaniaThe content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticls, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.To access the full program, go topce.is/IBD 

This podcast is the last in a series of four featuring IBD Dr Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, Dr Bernasko reviews the best practices for collaborating with primary care for optimal health maintenance in IBD patients, including cancer screening, bone health, immunizations, and more.  Presenter:Nana Bernasko, DNP, CRNP, WHNP-BCAssistant ProfessorDivision of Gastroenterology and Hepatology  Department of MedicinePenn State University Medical CenterHershey, PennsylvaniaThe content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticals, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.To access the full program, go topce.is/IBD 

In this second of two podcasts, 2 experts in migraine provide clinical pearls focused on preventing migraine. Listen as they discuss patient factors that indicate preventive treatment is warranted, the range of available preventive treatments and their use in practice, and strategies for engaging patients in their care.This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.Contributors:Karen A. Williams, DNP, FNP-BC, AQHPresidentKDW Health ManagementPensacola, FloridaDr Williams: consultant/advisor/speaker: Biohaven.Maureen Moriarty, DNP, ANP-BCAssociate Professor DirectorMalek School of Nursing ProfessionsMarymount UniversityArlington, VirginiaOwnerMoriarty AssociatesWestminster, MarylandDr Moriarty: consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly; researcher: Teva.

In this first of two podcasts, 2 experts in migraine provide valuable information on the differential diagnosis of migraine, including screening tools and techniques to incorporate into your practice. Additionally, they detail acute treatment options ranging from nonpharmacologic to over-the-counter to novel prescription pharmacologic therapies and discuss their use in the acute migraine management paradigm. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.Contributors:Karen A. Williams, DNP, FNP-BC, AQHPresidentKDW Health ManagementPensacola, FloridaDr Williams: consultant/advisor/speaker: Biohaven.Maureen Moriarty, DNP, ANP-BCAssociate Professor DirectorMalek School of Nursing ProfessionsMarymount UniversityArlington, VirginiaOwnerMoriarty AssociatesWestminster, MarylandDr Moriarty: consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly; researcher: Teva.

In this second of two podcasts, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP. Unique considerations of the drug and surgical options are discussed. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.Contributors:Hanny Al-Samkari, MDAssistant ProfessorHarvard Medical SchoolAttending Hematologist and Clinical InvestigatorDivision of Hematology OncologyMassachusetts General HospitalBoston, MassachusettsChristopher Nelson, ACNP-BC, MBANurse PractitionerHematology and OncologyAvera Cancer InstituteAvera St Luke's HospitalAberdeen, South DakotaDr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.Contributors:Hanny Al-Samkari, MDAssistant ProfessorHarvard Medical SchoolAttending Hematologist and Clinical InvestigatorDivision of Hematology OncologyMassachusetts General HospitalBoston, MassachusettsChristopher Nelson, ACNP-BC, MBANurse PractitionerHematology and OncologyAvera Cancer InstituteAvera St Luke's HospitalAberdeen, South DakotaDr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

In this second of 2 podcasts episodes on the management of painful vaso-occlusive crises in patients with sickle cell disease, listen to Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss  available treatment options for the prevention of painful vaso-occlusive events, and provide emergency department and outpatient setting recommendations on the proper use and indications for hydroxyurea, L-glutamine, and P-selecting blocking antibody crizanlizumab. This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmacology credit for NPs. To receive credit for this program, go to pce.is/sickle.Contributors:Michael R. DeBaun, MD, MPHDirectorVanderbilt-Meharry Center for Excellence in Sickle Cell DiseaseProfessorPediatrics and MedicineVice Chair for Clinical and Translational ResearchDepartment of PediatricsJ.C. Peterson Chair in PediatricsNashville, TennesseeMichael R. DeBaun, MD, MPH: consulting, speaker, and advisory board fees: Forma, GBT, Novartis, and Vertix.Alison Towerman, RN, MSN, CPNPPediatric Nurse PractitionerDepartment of Pediatrics, Division of Hematology/OncologyWashington University School of Medicine in St. LouisSt. Louis, Missouri Ms. Towerman has no relevant financial relationships to disclose.

In this first of 2 podcasts episodes, Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss  best practices for the management of painful vaso-occlusive crises (VOCs) in patients with sickle cell disease, review the disease pathophysiology, and provide emergency department and outpatient setting recommendations on nonpharmacologic and pharmacologic management of painful VOCs.  This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmacology credit for NPs. To receive credit for this program, go to pce.is/sickle.Contributors:Michael R. DeBaun, MD, MPHDirectorVanderbilt-Meharry Center for Excellence in Sickle Cell DiseaseProfessorPediatrics and MedicineVice Chair for Clinical and Translational ResearchDepartment of PediatricsJ.C. Peterson Chair in PediatricsNashville, TennesseeMichael R. DeBaun, MD, MPH: consulting, speaker, and advisory board fees: Forma, GBT, Novartis, and Vertix.Alison Towerman, RN, MSN, CPNPPediatric Nurse PractitionerDepartment of Pediatrics, Division of Hematology/OncologyWashington University School of Medicine in St. LouisSt. Louis, Missouri Ms. Towerman has no relevant financial relationships to disclose.

In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.Contributors:Joleen Hubbard MDCathy Eng, MDStephanie Andrews, MS, APRN-CMs Andrews: fees for non-CME/CE services: Genentech.Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.

In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for metastatic colorectal cancer. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.Contributors:Joleen Hubbard MDCathy Eng, MDStephanie Andrews, MS, APRN-CMs Andrews: fees for non-CME/CE services: Genentech.Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.